TY - JOUR
T1 - Gut microbiota and majore depressive disorder
T2 - A systematic review and meta-analysis
AU - Sanada, Kenji
AU - Nakajima, Shinichiro
AU - Kurokawa, Shunya
AU - Barceló-Soler, Alberto
AU - Ikuse, Daisuke
AU - Hirata, Akihito
AU - Yoshizawa, Akira
AU - Tomizawa, Yoshihiro
AU - Salas-Valero, Montserrat
AU - Noda, Yoshihiro
AU - Mimura, Masaru
AU - Iwanami, Akira
AU - Kishimoto, Taishiro
N1 - Funding Information:
Within the past three years, KS has received a research grant from Japan Dairy Association (J-milk) and speaker's honoraria from Eli Lilly and Dainippon Sumitomo Pharma. MM has received speaker's honoraria from Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin.Also, he received grants from Daiichi Sankyo, Eisai, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi and Tsumura. TK has received consultant fees from Otsuka, Pfizer, Dainippon Sumitomo, and speaker's honoraria from Banyu, Eli Lilly, Dainippon Sumitomo, Janssen, Novartis, Otsuka, and Pfizer.All other authors declare no conflicts of interest.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Background: Growing attention has been paid to the field of gut microbiota for mental disorders over the last decade. However, to our knowledge, no studies have conducted systematic reviews on the association between gut microbiota and major depressive disorder (MDD) in both interventional and non-interventional studies. Methods: We conducted a systematic review and meta-analysis of 16 studies (10 observational [701 participants] and six interventional trials [302 participants]) examining gut microbiota in patients with MDD. The primary outcome measures were differences in the profile of microbiota inthe observational studies, and symptom changes for depression between pre- and post-intervention with probiotics in the interventional trials. Results: In the observational studies, significant reductions in several taxa at the family and genus levels were observed in patients with MDD compared to non-depressed controls. In the interventional studies with probiotics, a significant improvement was found in depressive symptomatology compared to controls (SMD = .-1.62, 95% CI = .-2.73 to -0.51, p< 0.01). Limitations: Lack of consideration of the effects of diet and pharmacotherapy was a possible limitation. Conclusions: Our results indicate that several taxa at the family and genus levels, specifically family Prevotellaceae, genus Coprococcus,and Faecalibacterium, were decreased in MDD compared to non-depressed controls in observational studies, and depressive symptoms were improved compared to controls in interventional studies with probiotics. Due to the limited number of studies, further studies considering diet and pharmacotherapy are needed to explore the relationships between gut microbiota and MDD in humans.
AB - Background: Growing attention has been paid to the field of gut microbiota for mental disorders over the last decade. However, to our knowledge, no studies have conducted systematic reviews on the association between gut microbiota and major depressive disorder (MDD) in both interventional and non-interventional studies. Methods: We conducted a systematic review and meta-analysis of 16 studies (10 observational [701 participants] and six interventional trials [302 participants]) examining gut microbiota in patients with MDD. The primary outcome measures were differences in the profile of microbiota inthe observational studies, and symptom changes for depression between pre- and post-intervention with probiotics in the interventional trials. Results: In the observational studies, significant reductions in several taxa at the family and genus levels were observed in patients with MDD compared to non-depressed controls. In the interventional studies with probiotics, a significant improvement was found in depressive symptomatology compared to controls (SMD = .-1.62, 95% CI = .-2.73 to -0.51, p< 0.01). Limitations: Lack of consideration of the effects of diet and pharmacotherapy was a possible limitation. Conclusions: Our results indicate that several taxa at the family and genus levels, specifically family Prevotellaceae, genus Coprococcus,and Faecalibacterium, were decreased in MDD compared to non-depressed controls in observational studies, and depressive symptoms were improved compared to controls in interventional studies with probiotics. Due to the limited number of studies, further studies considering diet and pharmacotherapy are needed to explore the relationships between gut microbiota and MDD in humans.
KW - Gut microbiota
KW - Major depressive disorder
KW - Meta-analysis
KW - Observational study
KW - Probiotics
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=85078539400&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078539400&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2020.01.102
DO - 10.1016/j.jad.2020.01.102
M3 - Review article
C2 - 32056863
AN - SCOPUS:85078539400
VL - 266
SP - 1
EP - 13
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
SN - 0165-0327
ER -